Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease

Simple item page
dc.contributor.authorAtuğ, Özlen
dc.contributor.authorYılmaz, Yusuf
dc.contributor.buuauthorUlukaya, Engin
dc.contributor.buuauthorGül, Özen Öz
dc.contributor.buuauthorArabul, Mahmut
dc.contributor.buuauthorGül, Cuma Bülent
dc.contributor.buuauthorOral, Arzu Yılmaztepe
dc.contributor.buuauthorAker, Sibel
dc.contributor.buuauthorDolar, Mahmut Enver
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Biyokimya Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Endokrinoloji Anabilim Dalı.tr_TR
dc.contributor.departmentUludağ Üniversitesi/Tıp Fakültesi/Dahiliye Anabilim Dalı.tr_TR
dc.contributor.orcid0000-0003-2467-9356tr_TR
dc.contributor.orcid0000-0003-0463-6818tr_TR
dc.contributor.orcid0000-0003-4518-5283tr_TR
dc.contributor.researcheridA-7063-2018tr_TR
dc.contributor.researcheridAAI-1005-2021tr_TR
dc.contributor.researcheridAAG-9177-2021tr_TR
dc.contributor.researcheridA-5841-2017tr_TR
dc.contributor.researcheridK-5792-2018tr_TR
dc.contributor.scopusid22936014300tr_TR
dc.contributor.scopusid6602927353tr_TR
dc.contributor.scopusid26040787100tr_TR
dc.contributor.scopusid15925230900tr_TR
dc.contributor.scopusid23988796000tr_TR
dc.contributor.scopusid23091316500tr_TR
dc.contributor.scopusid12795285000tr_TR
dc.contributor.scopusid6602075084tr_TR
dc.date.accessioned2021-11-15T08:29:20Z
dc.date.available2021-11-15T08:29:20Z
dc.date.issued2009-06
dc.description.abstractObjectives: Levels of soluble receptor for advanced glycation endproducts (sRAGE) have been linked to several components of the metabolic syndrome. We tested the hypothesis that plasma levels of sRAGE may be associated with non-alcoholic fatty liver disease. Design and methods: We enrolled subjects with definite nonalcoholic steatohepatitis (NASH, n=40), borderline NASH (n=8), simple fatty liver (n=9) and healthy controls (n=14). Plasma levels of sRAGE were measured by ELISA. Results: Concentrations of sRAGE were significantly lower in patients with definite NASH (1080 +/- 392 pg/mL, P<0.01) and borderline NASH (1050 +/- 278 pg/mL, P<0.05) compared to controls (1480 +/- 387 pg/mL). Levels of sRAGE were significantly and inversely correlated with ALT (r=-0.30, P<0.05) and AST (r=-0.23, P<0.05). Conclusion: Plasma levels of sRAGE are significantly reduced in definite and borderline NASH.en_US
dc.identifier.citationYılmaz, Y. vd. (2009). "Decreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver disease". Clinical Biochemistry, 42(9), 802-807.en_US
dc.identifier.endpage807tr_TR
dc.identifier.issn0009-9120
dc.identifier.issue9tr_TR
dc.identifier.pubmed19217891tr_TR
dc.identifier.scopus2-s2.0-67349263467tr_TR
dc.identifier.startpage802tr_TR
dc.identifier.urihttps://doi.org/10.1016/j.clinbiochem.2009.02.003
dc.identifier.urihttps://www.sciencedirect.com/science/article/pii/S0009912009000848
dc.identifier.urihttp://hdl.handle.net/11452/22650
dc.identifier.volume42tr_TR
dc.identifier.wos000266295900008tr_TR
dc.indexed.pubmedPubmeden_US
dc.indexed.scopusScopusen_US
dc.indexed.wosSCIEen_US
dc.language.isoenen_US
dc.publisherPergamon-Elsevier Scienceen_US
dc.relation.collaborationYurt içitr_TR
dc.relation.journalClinical Biochemistryen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergitr_TR
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectFatty liveren_US
dc.subjectBiological markersen_US
dc.subjectReceptor for advanced glycation endproducts (RAGE)en_US
dc.subjectEnzyme-linked immunosorbent assayen_US
dc.subjectEnd-products agesen_US
dc.subjectInsulin-resistanceen_US
dc.subjectSerum-levelsen_US
dc.subjectRageen_US
dc.subjectFormen_US
dc.subjectPathogenesisen_US
dc.subjectGalectin-3en_US
dc.subjectProteinen_US
dc.subjectMedical laboratory technologyen_US
dc.subject.emtreeAdvanced glycation end product receptoren_US
dc.subject.emtreeAlanine aminotransferaseen_US
dc.subject.emtreeAdulten_US
dc.subject.emtreeAlanine aminotransferase blood levelen_US
dc.subject.emtreeControlled studyen_US
dc.subject.emtreeArticleen_US
dc.subject.emtreeDisease associationen_US
dc.subject.emtreeEnzyme linked immunosorbent assayen_US
dc.subject.emtreeFatty liveren_US
dc.subject.emtreeFemaleen_US
dc.subject.emtreeHumanen_US
dc.subject.emtreeHuman tissueen_US
dc.subject.emtreeInsulin resistanceen_US
dc.subject.emtreeLiver biopsyen_US
dc.subject.emtreeMajor clinical studyen_US
dc.subject.emtreeMaleen_US
dc.subject.emtreeNonalcoholic fatty liveren_US
dc.subject.emtreePriority journalen_US
dc.subject.emtreeProtein blood levelen_US
dc.subject.meshAdulten_US
dc.subject.meshEnzyme-linked immunosorbent assayen_US
dc.subject.meshFatty liveren_US
dc.subject.meshHumansen_US
dc.subject.meshMiddle ageden_US
dc.subject.meshReceptors, immunologicen_US
dc.subject.scopusAdvanced Glycation End Product Receptor; 6 N Carboxymethyllysine; Glycationen_US
dc.subject.wosMedical laboratory technologyen_US
dc.titleDecreased plasma levels of soluble receptor for advanced glycation endproducts (sRAGE) in patients with nonalcoholic fatty liver diseaseen_US
dc.typeArticle
dc.wos.quartileQ2en_US

Files

License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description:
Download

Collections

Web of Science
Scopus